Your browser doesn't support javascript.
loading
Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
Bull-Hansen, Bente; Berstad, Maria B; Berg, Kristian; Cao, Yu; Skarpen, Ellen; Fremstedal, Ane Sofie; Rosenblum, Michael G; Peng, Qian; Weyergang, Anette.
Afiliación
  • Bull-Hansen B; Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Berstad MB; Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Berg K; Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Cao Y; Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.
  • Skarpen E; Current address: The Scripps Research Institute, Department of Chemistry, La Jolla, CA, USA.
  • Fremstedal AS; Department of Biochemistry, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Rosenblum MG; Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Peng Q; Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.
  • Weyergang A; Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Oncotarget ; 6(14): 12436-51, 2015 May 20.
Article en En | MEDLINE | ID: mdl-26002552
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Inmunotoxinas / Sistemas de Liberación de Medicamentos / Receptor ErbB-2 / Terapia Molecular Dirigida / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: Noruega
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Inmunotoxinas / Sistemas de Liberación de Medicamentos / Receptor ErbB-2 / Terapia Molecular Dirigida / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: Noruega